4527 — Rohto Pharmaceutical Co Cashflow Statement
0.000.00%
- ¥541bn
- ¥529bn
- ¥271bn
- 82
- 39
- 16
- 42
Annual cashflow statement for Rohto Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 21,730 | 23,006 | 27,953 | 34,290 | 41,518 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 924 | 561 | 1,792 | 1,112 | -563 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -10,482 | -10,238 | -10,167 | -12,278 | -15,374 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 19,109 | 20,077 | 27,251 | 30,925 | 34,268 |
Capital Expenditures | -6,433 | -10,304 | -11,328 | -9,908 | -8,912 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -2,972 | 67 | -5,078 | -3,268 | -7,405 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -9,405 | -10,237 | -16,406 | -13,176 | -16,317 |
Financing Cash Flow Items | -194 | -216 | -698 | -1,641 | -7,086 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -1,603 | -2,347 | 3,470 | -16,199 | -13,784 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 7,320 | 7,589 | 18,650 | 6,786 | 8,870 |